Figure 1. Adoptive transfer of Cd18^wt CD4⁺CD25⁺CD127^– Tregs into affected Cd18^hypo mice resolves the psoriasiform skin disease.

(A) Representative clinical pictures of a Cd18^hypo mouse with severe psoriasiform skin disease before (left panel) and almost complete resolution 42 days after the first adoptive transfer with Tregs from Cd18^wt mice (right panel). An adapted PASI score was used to assess the severity of the psoriasiform phenotype before and after adoptive transfer with Cd18^wt Tregs (B) or Cd18^hypo Tregs (C). Data are representative of 3 independent experiments. (D) An improvement of the psoriasiform skin disease in affected Cd18^hypo mice was observed after intradermal injection of Cd18^wt Tregs once weekly for 3 weeks. (E and F) The adapted PASI score of affected Cd18^hypo mice treated with Cd18^wt Tregs is significantly reduced compared with that of mice treated with Cd18^hypo Tregs. **P < 0.01, using Student’s t test. Original magnification, × 1 (A and D).